Response to DDAVP in children with von Willebrand disease type 2

Hamostaseologie

Volumn 29, Issue 2, 2009, Pages 143-148

  Schneppenheim, R ^a   Budde, U ^b   Beutel, K ^a   Hassenpflug, W A ^a   Hauch, H ^c   Obser, T ^a   Oyen, F ^a   Schneppenheim, S ^a,b   Schrum, J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Coagulation Laboratory   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Desmopressin; Von Willebrand disease

Indexed keywords

DESMOPRESSIN; POLYMER;

ARTICLE; CORRELATION ANALYSIS; EVALUATION; GENE IDENTIFICATION; GENE MUTATION; PHENOTYPE; PROSPECTIVE STUDY; VON WILLEBRAND DISEASE;

EID: 66749109518     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617014     Document Type: Article

References (14)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-459.
2. Werner EJ, Broxson EH, Tucker EL et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893-898.
3. Rodeghiero F, Castaman G. Treatment of von Willebrand disease. Semin Hematol 2005; 42: 29-35.
4. Kaufmann JE, Oksche A, Wollheim CB et al. Va- sopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. Blood 2000; 106: 107-116.
5. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The First 20 Years. Blood 1997; 90: 2515-2521.
6. Goodeve A, Eikenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Wille- brand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112-121.
7. Budde U, Schneppenheim R, Eikenboom J et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 6: 762-771.
8. James PD, Notley C, Hegadorn C et al. The mu- tational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109: 145-154.
9. Castaman G, Lethagen S, Federici AB et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111: 3531-3539.
10. Federici AB, Mazurier C, Berntorp E et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103: 2032-2038.
11. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-2114.
12. Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost 2006; 32: 514-521.
13. Ledford MR, Rabinowitz I, Sadler JE et al. New variant of von Willebrand disease type II with markedly increased levels of von Willebrand factor antigen and dominant mode of inheritance: von Willebrand disease type IIC Miami. Blood 1993; 821: 169-175
14. Casonato A, Sartorello F, Cattini MG et al. An Arg760Cys mutation in the consensus sequence of the vonWillebrand factor propeptide cleavage site is responsible for a new vonWillebrand disease variant. Blood 2003; 101: 151-156.